e-ISSN: Pending
Negative / Null Result ReportOpen accessEconomics, Econometrics and Finance· cited by 9

Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study

Ariadna Tibau; Edward R. Scheffer Cliff; Alejandra Romano; María Borrell; Consolación Moltó; Aaron Seth Kesselheim · 2025 · EClinicalMedicine

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Background: The accelerated approval pathway allows the FDA to approve drugs for serious conditions based on promising surrogate measures, with confirmatory studies required later. If subsequent testing shows an unfavorable benefit-risk profile, the indication may be withdrawn. This study aimed to identify factors associated with the withdrawal of drug indications following accelerated approval. Methods: In this retrospective cohort study, we identified FDA-approved drugs for solid and hematologic cancers from 1992 to 2022 and extracted factors present at the time of accelerated approval, incl

Abstract by Ariadna Tibau; Edward R. Scheffer Cliff; Alejandra Romano; María Borrell; Consolación Moltó; Aaron Seth Kesselheim, EClinicalMedicine (2025) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1016/j.eclinm.2025.103088